Index
By TNW
About Index
Trending news
Analyze
Pricing
Sign up or sign in
Sarepta Therapeutics
2937
Sarepta Therapeutics
Sarepta Therapeutics – formerly AVI BioPharma – remains focused on developingfirst-in-class, RNA-based therapeutics to improve and save
I work here
Suggest edits
sarepta.com
Technology
>
Biotechnology
B2b
Raised
$100M
More info
Elsewhere
Also headquartered in Cambridge
MIT
Raspberry Pi
ARM
Xconomy
HubSpot
Mobile.co
nuTonomy
Biogen
Hopper
General Catalyst
Companies in the same industry
Sequenta
Benevir Biopharm
Personalis, Inc.
Perlstein Lab
VivoSight OCT
CDx Life
Pluristem
Transgenomic
Strain Merchant
Edimer Pharma
Alexa global traffic share
Overview
Funding
1
Acquisitions
1
Add info
Latest funding
Post-IPO debt
$100,000,000
Employees
Team size
50+
Locations
HQ
Cambridge
,
United States
Headquarters
$100,000,000
Post-IPO debt
GlobeNewswire News Room
,
Reuters
Sarepta Therapeutics Secures $100 Million in Debt Financing
Xconomy
Bio Roundup: Precision Med and Google, Heron, Lilly, Sarepta & More
Health
Science
Xconomy
Sarepta Stock Down as FDA Seeks More Data from Rival Duchenne Drug
Health
Earnings
The Motley Fool
Why Envision Healthcare Holdings, Sarepta Therapeutics, and ABM Industries Jumped Today
Stock markets
Technology
Health
The Motley Fool
Why Sarepta Therapeutics Shares Are Jumping 10% Today
The Motley Fool
Why Sarepta Therapeutics Shares Skyrocketed Today
The Motley Fool
Why Sarepta Therapeutics Shares Skyrocketed 48% in May
The Motley Fool
Why Sarepta Therapeutics, Signet Jewelers, and DeVry Education Group Slumped Today
Stock markets
Health
The Motley Fool
Why Sarepta Therapeutics Shares Are Tumbling 19% Today
The Motley Fool
Here's Why Sarepta Therapeutics' Stock Is Surging Higher Today
Xconomy
Sarepta Saga Drags On as FDA Delays Decision on Duchenne Drug
Health
The Motley Fool
Forget Sarepta Therapeutics, This DMD Stock Could Be A Better Buy
The Motley Fool
What's Sarepta Therapeutics Inc.'s Next Move?
Health
The Motley Fool
3 Things You Need to Know Now That Sarepta Therapeutics Has Reported First-Quarter Results
Health
Stock markets
The Motley Fool
Why Sarepta Therapeutics Inc. Is Up Big Today
The Motley Fool
Why Sarepta Therapeutics, Allegheny Technologies, and Capital Product Partners Slumped This Morning
Stock markets
Earnings
The Motley Fool
Why Sarepta Therapeutics' Stock Is Crashing Today
The Motley Fool
Why Sarepta Therapeutics Inc. Is Bouncing Back Today
The Motley Fool
Why Las Vegas Sands, Sarepta Therapeutics, and United Continental Holdings Slumped Today
Stock markets
Earnings
The Motley Fool
Down 41%: Is Sarepta Therapeutics Worth the Risk?
MIT
Raspberry Pi
ARM
Xconomy
HubSpot
Mobile.co
nuTonomy
Hopper
General Catalyst
Sequenta
Benevir Biopharm
Personalis, Inc.
Perlstein Lab
VivoSight OCT
CDx Life
Pluristem
Transgenomic
Strain Merchant
Edimer Pharma